CIT expands US presence

Appoints vice-president of business development North America

CIT, a French non-clinical CRO, has opened a US subsidiary, CITox, in Boston, Massachusetts, to spearhead the planned expansion of its US activities.

The company has appointed Bernard Galat as vice-president, business development, North America, who will be based in the Boston office.

The US represents 15% of CIT’s current sales; the aim is to increase this to 30% in three to five years.

Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron, Parexel and Carestat.

‘This is an exciting time to be joining CIT as we expand the availability of our services in monoclonal antibody therapies, tissue cross-reactivity, functional genomics, safety pharmacology and carcinogenicity, including transgenic models,’ he said.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Subscribe now